ChitogenX, Inc. is a clinical stage biotech company, which engages in the development of therapeutic soft tissue repair technologies for orthopaedic and sports medicine surgeries. The company is headquartered in Kirkland, Quebec. The company went IPO on 2017-10-10. The firm is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The firm is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Follow-Up Questions
Quelle est la performance du prix de l'action CHNXF ?
Le prix actuel de CHNXF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Chitogenx Inc ?
Chitogenx Inc appartient à l'industrie N/A et le secteur est N/A
Quelle est la capitalisation boursière de Chitogenx Inc ?
La capitalisation boursière actuelle de Chitogenx Inc est de $0
Est-ce que Chitogenx Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Chitogenx Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
